Literature DB >> 1109785

Inhibition of renal tubular transport of methotrexate by probenecid.

R S Bourke, G Chheda, A Bremer, O Watanabe, D B Tower.   

Abstract

The mechanism of excretion of methotrexate (MTX) has been investigated in the monkey. Under steady-state conditions of varied plasma levels of MTX, it was determined that MTX was excreted by renal tubular transport as well as by glomerular filtration. The maximum rate of renal tubular transport of MTX (81 mug/min) was attained at plasma levels of MTX from 6 to 8 mug/ml. Correspondingly, the rate of clearance of MTX from plasma was shown to diminish from a value that was 3-fold greater than the glomerular filtration rate at plasma levels of MTX from 6 to 32 mug/ml. Pretreatment of animals with probenecid (700 mg/sq m) totally inhibited renal tubular transport of MTX when MTX was administered in doses from 1.8 to 621 mg/sq m. Following inhibition of renal tubular transport of MTX by probenecid, steady-state plasma levels of MTX in animals pretreated with probenecid (700 mg/sq m) was reduced by a factor of 2.6 from values determined in non-probenecid-pretreated control animals receiving similar varied doses of MTX (1.8 P to greater than 600 mg/sq m). The mode of i.v. injection of MTX was seen to effect the concentration of MTX in plasma. Initial loading followed by continuous sustaining infusion of MTX provided stable and higher levels of MTX in plasma than was determined in controls or in experimental animals pretreated with probenecid and receiving identical doses of MTX by single bolus injection.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1109785

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

Review 1.  Combination therapy for autoimmune diseases: the rheumatoid arthritis model.

Authors:  N Fathy; D E Furst
Journal:  Springer Semin Immunopathol       Date:  2001

Review 2.  Protein binding drug displacement interactions fact or fiction?

Authors:  J J MacKichan
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

Review 3.  Saturable pharmacokinetics in the renal excretion of drugs.

Authors:  C A van Ginneken; F G Russel
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

Review 4.  Renal organic anion transporters (SLC22 family): expression, regulation, roles in toxicity, and impact on injury and disease.

Authors:  Li Wang; Douglas H Sweet
Journal:  AAPS J       Date:  2012-10-09       Impact factor: 4.009

Review 5.  Pharmacokinetic drug interactions of commonly used anticancer drugs.

Authors:  F M Balis
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

6.  Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits.

Authors:  H Iven; H Brasch; J Engster
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  Mathematical modeling -- guide to high-dose methotrexate infusion therapy.

Authors:  S D Reich
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

8.  Influence of the antibiotics piperacillin, doxycycline, and tobramycin on the pharmacokinetics of methotrexate in rabbits.

Authors:  H Iven; H Brasch
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 9.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

10.  Pharmacologic studies on the dibutyl and gamma-monobutyl esters of methotrexate in the rhesus monkey.

Authors:  A Rosowsky; H T Abelson; G P Beardsley; W D Ensminger; D W Kufe; G Steele; E J Modest
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.